Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Related Research units
Abstract
Epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) are crucial targets in cancer therapy. Combined inhibition of both targets yielded synergistic effects in vitro and in vivo in several cancer entities. However, the impact of EGFR and mTOR expression and combined inhibition in neuroendocrine lung tumors other than small-cell lung cancer remains unclear.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 3 |
| ISSN | 0028-3835 |
| Publication status | Published - 2012 |
| pubmed | 22378048 |
|---|
